{"id":14909,"date":"2026-06-02T22:30:00","date_gmt":"2026-06-02T20:30:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=107b364ffdab845c473be2091e07f593"},"modified":"2026-06-02T22:30:00","modified_gmt":"2026-06-02T20:30:00","slug":"nanodetection-technology-and-oligomerix-announce-exclusive-global-licensing-agreement-for-breakthrough-neurodegenerative-diagnostic-antibodies","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=14909","title":{"rendered":"NanoDetection Technology\u2122 and Oligomerix\u2122 Announce Exclusive Global Licensing Agreement for Breakthrough Neurodegenerative Diagnostic Antibodies"},"content":{"rendered":"

FRANKLIN, Ohio & BRONX, N.Y.--(BUSINESS WIRE)--NanoDetection Technology, Incorporated (NDT) and Oligomerix, Inc. today announced the execution of an exclusive worldwide license agreement. Under the terms of the agreement, NanoDetection has secured exclusive rights to develop and commercialize diagnostic tests utilizing a proprietary panel of nine Tau antibodies discovered by Oligomerix, Inc. and widely recognized for their scientific importance in neurodegenerative disease research. Oligomerix retains rights to therapeutic applications of the antibody panel.<\/p><\/a><\/a>

\nQuantifying Protein State Transitions<\/span><\/b><\/p>

\nThe licensed antibody portfolio represents a significant advancement in the characterization of Alzheimer\u2019s disease and other Tau-related pathologies. These highly specialized reagents enable differentiation among distinct Tau species, including cleavage-specific and conformationally altered forms located within the protein filament core.<\/p>

\nThis degree of specificity provides a foundation for distinguishing Alzheimer\u2019s disease-associated Tau pathology from related neurodegenerative disorders, including Frontotemporal Dementia (FTD), Progressive Supranuclear Palsy (PSP), and Corticobasal Degeneration (CBD), while also enabling quantitative characterization of disease-associated protein aggregation.<\/p>

\nNanoDetection has integrated these antibodies into its proprietary TRACE-Tau\u2122 platform, establishing a quantitative framework for monitoring protein-state transitions across the Alzheimer\u2019s disease pathological continuum. The resulting assays are being developed for deployment on NanoDetection\u2019s proprietary Luminorix\u2122<\/sup><\/b> instrument system using the company\u2019s Accuglo\u2122<\/sup><\/b> chemiluminescent assay architecture.<\/p>

\nHuman Sample Characterization and Translational Validation<\/span><\/b><\/p>

\nData generated from analyses of multiple Alzheimer\u2019s disease patient samples have demonstrated detection and characterization of aggregated Tau species across a variety of human sample types, supporting the translational relevance of the antibody platform.<\/p>

\nValidation of the technology in cerebrospinal fluid remains promising as NanoDetection, in collaboration with the UMass Chan Medical School Morphology and SCOPE cores, continues to advance clinical verification of the diagnostic platform.<\/b><\/p>

\nUnlike conventional assays that primarily quantify total or phosphorylated Tau, the NanoDetection platform is designed to specifically interrogate aggregated Tau species believed to be more closely associated with active disease pathology.<\/p>

\nLeadership Commentary<\/span><\/b><\/p>

\n\u201cThis agreement represents a major strategic milestone for NDT,\u201d said Douglas Durand, Chief Executive Officer of NanoDetection Technology<\/b>. \u201cThe Oligomerix antibody portfolio provides NDT with a powerful scientific and commercial foundation for the development of next-generation protein characterization and neurodegenerative diagnostic platforms.\u201d James Moe, Chief Executive Officer of Oligomerix<\/b>, added: \u201cWe are pleased to partner with NDT as they advance diagnostic applications utilizing the Oligomerix Tau antibody portfolio. We believe these antibodies may provide important tools for characterizing aggregated and conformational Tau species associated with neurodegenerative disease and related conditions, while further expanding Oligomerix\u2019s platform of Tau-focused technologies.\u201d<\/p>

\nAbout NanoDetection Technology, Incorporated<\/span><\/b><\/p>

\nLocated in Franklin, Ohio, NanoDetection Technology develops advanced diagnostic platforms for complex diseases, including neurodegeneration, oncology, and infectious disease. Its Luminorix\u2122<\/sup><\/b> instrument system is designed to translate high-precision assay technologies into rapid clinical applications.<\/p>

\nAbout Oligomerix, Incorporated<\/span><\/b><\/p>

\nHeadquartered in the Bronx, New York, Oligomerix is a clinical-stage biotechnology company focused on discovering and developing novel small-molecule inhibitors of protein self-association for Alzheimer\u2019s disease and rare neurodegenerative disorders, including Progressive Supranuclear Palsy and Frontotemporal Dementia. Oligomerix\u2019s lead compound, OLX-07010<\/b>, has completed Phase 1a and is preparing to enter clinical trials in Alzheimer\u2019s disease patients.<\/p> Contacts<\/b>

\nMedia Contact, NanoDetection Technology\u2122<\/sup><\/b>Douglas N. Durand\nPresident, Chief Executive Officer, NanoDetection Technology\u2122<\/sup>D.Durand@ndtbio.com<\/a> | 727-643-5392\n\nwww.ndtbio.com<\/b><\/a> | www.linkedin.com\/company\/nanodetection-technology<\/a>\n<\/b>Media Contact, Oligomerix\u2122<\/sup><\/b>James Moe\nPresident, Chief Executive Officer, Oligomerix\u2122<\/sup>Jmoe@oligomerix.com<\/a> | <\/b>203-564-6149\n\nwww. oligomerix.com<\/b><\/a> | www.linkedin.com\/company\/oligomerix-inc\/<\/a><\/b><\/p>","protected":false},"excerpt":{"rendered":"

FRANKLIN, Ohio & BRONX, N.Y.–(BUSINESS WIRE)–NanoDetection Technology, Incorporated (NDT) and Oligomerix, Inc. today announced the execution of an exclusive worldwide license agreement. Under the terms of the agreement, NanoDetection has secured excl…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-14909","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/14909","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14909"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/14909\/revisions"}],"predecessor-version":[{"id":14910,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/14909\/revisions\/14910"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14909"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14909"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14909"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}